A pharmaceutical composition is provided comprising a highly soluble arsenic carbonate and/or bicarbonate compound and which is useful in the treatment of a variety of cancers, including acute promyelocytic leukaemia. The arsenic carbonate and/or bicarbonate salt acts as a solid, and so orally deliverable, improved bioequivalent delivery form of arsenic trioxide IV solutions.